1638983-52-4 Usage
Uses
Used in Pharmaceutical Synthesis:
MPMP is utilized as a key intermediate in the development of various pharmaceuticals and organic compounds, owing to its distinctive structural attributes that facilitate the creation of diverse medicinal agents.
Used in Neurological Disorder Treatment:
In the medical field, MPMP has been investigated for its potential therapeutic applications in treating neurological disorders, capitalizing on its chemical properties to address specific conditions.
Used in Cancer Treatment Research:
MPMP is also being studied for its possible role in cancer treatment, with research focusing on its ability to target and combat cancer cells effectively.
Used in Enzyme Inhibition:
Furthermore, MPMP has demonstrated inhibitory effects on certain enzymes, positioning it as a promising candidate for drug development and medicinal chemistry research aimed at creating novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1638983-52-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,3,8,9,8 and 3 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1638983-52:
(9*1)+(8*6)+(7*3)+(6*8)+(5*9)+(4*8)+(3*3)+(2*5)+(1*2)=224
224 % 10 = 4
So 1638983-52-4 is a valid CAS Registry Number.
1638983-52-4Relevant academic research and scientific papers
PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS
-
, (2015/11/25)
In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.
THERAPEUTIC INHIBITORY COMPOUNDS
-
, (2015/07/16)
The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.
HETEROCYCLIC DERIVATES
-
, (2014/12/12)
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B,W, X, Y and Z are as defined herein.
